FDA Adverse Event Injury Summary report: N

CANCELLO-PURE WEDGE

MDR report key: 1944331 · Received December 10, 2010

Report

Report Number
3002719998-2010-00005
Event Type
Injury
Date Received
December 10, 2010
Date of Event
October 5, 2010
Report Date
December 8, 2010
Manufacturer
RTI BIOLOGICS
Product Code
MQV
PMA / PMN Number
K072327
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
TN, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

INVESTIGATION: ACCORDING TO THE MFG RECORDS, THE GRAFT WAS MANUFACTURED TO SPECIFICATION. THE GRAFT UNDERWENT TWO VALIDATED STERILIZATION METHODS; BIOCLEANSE AND POST PACKAGING GAMMA IRRADIATION AT A VALIDATED DOSE TO ACHIEVE A STERILITY ASSURANCE LEVEL (SAL) OF 10-6 PRIOR TO RELEASE. RE-REVIEW OF BIOCOMPATIBILITY VALIDATIONS AND COMPARISON OF CURRENT PROCESSING TECHNIQUES, SAMPLES OF REPRESENTATIVE MFG EPISODES, FOOT/ANKLE LITERATURE REVIEW AND ADDITIONAL IN VIVO AND IN VITRO TESTING OF VARIOUS BOVINE PRODUCTS WAS CONDUCTED. RESULTS OF INVESTIGATION: MANY FACTORS MAY LEAD TO NON-UNION. EXAMPLES INCLUDE DECREASED BLOOD SUPPLY, WEIGHT, INFECTION, POOR GLYCEMIC CONTROL, NONCOMPLIANCE WITH THERAPY, MEDICATIONS (E.G STEROIDS), ADJUNCT HARDWARE/IMPLANTS, THE PHYSICAL LOCATION OF THE SURGICAL SITE, OR A PROLONGED INFLAMMATORY RESPONSE. CONCLUSION: GRAFTS ASSOCIATED WITH LOT#: 1-081028 PASSED ALL RTI RELEASE CRITERIA PRIOR TO DISTRIBUTION. TO DATE, THE RESULTS OF OUR INVESTIGATION HAVE NOT IDENTIFIED AN AGENT OR EVENT INTRINSIC TO THE GRAFT MATERIAL OR PROCESSING METHODOLOGY THAT WOULD CONTRIBUTE TO THE TYPE OF EXPERIENCE REPORTED IN THIS COMPLAINT.

Description of Event or Problem · 1

ON (B)(6) 2009, THE PT UNDERWENT A SURGICAL PROCEDURE WHERE A 12 MM EVANS BONE WEDGE XENOGRAFT WAS IMPLANTED. ON (B)(6) 2010, THE PT UNDERWENT REVISION SURGERY DUE TO NON-UNION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 CANCELLO-PURE WEDGE BOVINE BONE VOID FILLER (MQV) MQV RTI BIOLOGICS 1-081028

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention